150 related articles for article (PubMed ID: 32700644)
1. Prediction of the impact of
Asari K; Takahashi H
Pharmacogenomics; 2020 Aug; 21(12):853-862. PubMed ID: 32700644
[No Abstract] [Full Text] [Related]
2. VKORC1 and CYP2C9 genotypic data-based dose prediction alone does not accurately predict warfarin dose requirements in some Malaysian patients.
Chua YA; Abdullah WZ; Yusof Z; Gan SH
Turk J Med Sci; 2015; 45(4):913-8. PubMed ID: 26422867
[TBL] [Abstract][Full Text] [Related]
3. Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors.
Lu Y; Yang J; Zhang H; Yang J
Clin Pharmacokinet; 2013 Jul; 52(7):567-81. PubMed ID: 23515956
[TBL] [Abstract][Full Text] [Related]
4. Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations.
Ohara M; Suzuki Y; Shinohara S; Gong IY; Schmerk CL; Tirona RG; Schwarz UI; Wen MS; Lee MTM; Mihara K; Nutescu EA; Perera MA; Cavallari LH; Kim RB; Takahashi H
Clin Pharmacokinet; 2019 Aug; 58(8):1077-1089. PubMed ID: 30815847
[TBL] [Abstract][Full Text] [Related]
5. A physiologically based pharmacokinetic/pharmacodynamic modeling approach for drug-drug interaction evaluation of warfarin enantiomers with sorafenib.
Wang Z; Xiang X; Liu S; Tang Z; Sun H; Parvez M; Ghim JL; Shin JG; Cai W
Drug Metab Pharmacokinet; 2021 Aug; 39():100362. PubMed ID: 34242938
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of Warfarin in a Diverse Patient Population.
Mak M; Lam C; Pineda SJ; Lou M; Xu LY; Meeks C; Lin C; Stone R; Rodgers K; Mitani G
J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):521-533. PubMed ID: 31064211
[TBL] [Abstract][Full Text] [Related]
7. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
[TBL] [Abstract][Full Text] [Related]
8. Effects of vitamin K epoxide reductase complex 1 gene polymorphisms on warfarin control in Japanese patients with left ventricular assist devices (LVAD).
Nakagita K; Wada K; Mukai Y; Uno T; Nishino R; Matsuda S; Takenaka H; Terakawa N; Oita A; Takada M
Eur J Clin Pharmacol; 2018 Jul; 74(7):885-894. PubMed ID: 29781049
[TBL] [Abstract][Full Text] [Related]
9. A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional.
Sridharan K; Sivaramakrishnan G
J Clin Pharm Ther; 2021 Jun; 46(3):640-648. PubMed ID: 33346393
[TBL] [Abstract][Full Text] [Related]
10. The Influence of VKORC1 Polymorphisms on Warfarin Doses in Thai Patients with Deep Vein Thrombosis.
Sermsathanasawadi N; Sritongsathian C; Pongrattanaman N; Praditsuktavorn B; Hongku K; Wongwanit C; Ruangsetakit C; Chinsakchai K; Mutirangura P; Poungvarin N
J Med Assoc Thai; 2015 Jun; 98(6):549-54. PubMed ID: 26219158
[TBL] [Abstract][Full Text] [Related]
11. Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithm.
Li X; Liu R; Yan H; Tang J; Yin JY; Mao XY; Yang F; Luo ZY; Tan SL; He H; Chen XP; Liu ZQ; Li Z; Zhou HH; Zhang W
J Clin Pharmacol; 2015 Mar; 55(3):251-7. PubMed ID: 25187307
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.
Sridharan K; Al Banna R; Malalla Z; Husain A; Sater M; Jassim G; Otoom S
Pharmacol Rep; 2021 Oct; 73(5):1405-1417. PubMed ID: 33811620
[TBL] [Abstract][Full Text] [Related]
13. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
[TBL] [Abstract][Full Text] [Related]
14. VKORC1 and CYP2C9 genotype distribution in Asian countries.
Gaikwad T; Ghosh K; Shetty S
Thromb Res; 2014 Sep; 134(3):537-44. PubMed ID: 24908449
[TBL] [Abstract][Full Text] [Related]
15. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
16. Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population.
Gaikwad T; Ghosh K; Kulkarni B; Kulkarni V; Ross C; Shetty S
Eur J Pharmacol; 2013 Jun; 710(1-3):80-4. PubMed ID: 23602689
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin.
Sangviroon A; Panomvana D; Tassaneeyakul W; Namchaisiri J
Drug Metab Pharmacokinet; 2010; 25(6):531-8. PubMed ID: 20930419
[TBL] [Abstract][Full Text] [Related]
18. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
[TBL] [Abstract][Full Text] [Related]
19. Effect of VKORC1 and CYP2C9 polymorphisms on warfarin dose requirement in Bangladeshi population.
Chowdhury ZS; Shahjin F; Akter F; Ahmed M; Islam MS; Bin Sayeed MS; Islam R; Hasnat A
Pak J Pharm Sci; 2017 Mar; 30(2):341-346. PubMed ID: 28649054
[TBL] [Abstract][Full Text] [Related]
20. Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin.
Yuen E; Gueorguieva I; Wise S; Soon D; Aarons L
J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):3-24. PubMed ID: 19941044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
